Access To Vaccines index

Access to Vaccines Index 2017

The first landscape analysis showing how vaccine companies are responding to calls to increase access to vaccines.

About the Index
Methodology
Who we are
Download the report

Access to Vaccines Index 2017

The first landscape of company action to increase access to vaccines

The Index finds a high level of diversity in how vaccine companies are improving access to vaccines for people living in poorer countries. GSK leads the three areas evaluated, with a strong performance from Sanofi across the board…

News

A look back at a year of vaccine announcements

13 Feb 2018
Vaccine companies have released 18 statements about their vaccines businesses since the first Access to Vaccines Index was published in March 2017. The Access to Medicine Foundation has reviewed these statements to give a sense of the level of momentum in the vaccines industry to improve access to vaccines.

New Access to Vaccines Index reveals first landscape of vaccine company actions to improve immunisation coverage

06 Mar 2017
The first Access to Vaccines Index will be published on Monday 6 March, 2017. It is the first tool of its kind to present the current landscape of vaccine company behaviour when it comes to making vaccines more accessible for the populations that need them.

Access to Vaccines Index webinar for investors – co hosted by PRI and ICCR

06 Mar 2017
On Wednesday 31 May, the Interfaith Center on Corporate Responsibility (ICCR), the Principles for Responsible Investment (PRI) and the Access to Medicine Foundation will co-host an investor webinar about the Access to Vaccines Index, focusing on access to vaccines as a material issue for investors in pharmaceutical companies.

UNICEF covers the upcoming Access to Vaccines Index

02 Nov 2016
Margot de Graaff from the UNICEF Netherlands magazine interviews Jayasree K Iyer and Suzanne Wolf regarding the pharmaceutical industry, the Access to Medicines Index and the upcoming Access to Vaccines Index.

Report cards

Detailed breakdown of each company’s access performances and opportunities to do more, as well as portfolio and pipeline analyses.

Cross-cutting analyses

How are vaccine companies responding to key global health challenges? Looking at how the first malaria and dengue vaccines are being deployed; and responses to emerging infectious diseases such as Ebola and Zika virus.

“Disease outbreaks will continue to occur.
Companies need to be at the table as governments and others work to build resilient health systems.”

Jayasree K. Iyer, Executive Director, Access to Medicine Foundation.

key finding:
R&D for vaccine adaptations

Adaptations to existing vaccines account for half of vaccine R&D projects

Index identifies wide variety of adaptations in the pipeline, together accounting for 48% of R&D projects…

key finding:
Vaccine pricing

When setting prices, all companies consider countries’ Gavi status – most also consider GNI per capita

Companies report considering 18 factors when setting vaccine prices, including development costs and the public health value of the vaccine…

key finding:
Aligning supply and demand

Companies take diverse approaches to aligning supply with demand

Companies take diverse approaches to aligning supply with demand, with four companies taking comparatively strong approaches…

The Access to Vaccines Index is funded by

NPL-logo-2016

The Access to Medicine Foundation is funded by

UKaid
Gates-Foundation
Ministry-of-foreign-affairs-of-the-Netherlands